Institute for Clinical Pharmacodynamics (United States)

Recent papers from Institute for Clinical Pharmacodynamics (United States)

1. Population Pharmacokinetic Analysis of Brensocatib in Adult and Adolescent Patients With Non‐Cystic Fibrosis BronchiectasisCPT Pharmacometrics & Systems Pharmacology · 2026
2. The immunogenicity database collaborative: a standardized, publicly available database for clinical immunogenicity observations and insightsFrontiers in Immunology · 2026
3. A single-cell atlas of ulcerative colitis reveals neutrophil–stromal circuits linked to biologic therapy resistanceFrontiers in Immunology · 2026
4. Nemonoxacin pharmacokinetics/pharmacodynamics against Escherichia coli in an in vitro dynamic urinary tract infection modelAntimicrobial Agents and Chemotherapy · 2026
5. B106-14 Population Pharmacokinetics Analysis of Treprostinil Using Data From Phase 1 and 2 Studies of Treprostinil Palmitil Inhalation PowderAmerican Journal of Respiratory and Critical Care Medicine · 2026
6. C103-11 PK/PD Modelling of the Anti-AREG Antibody PMG1015 Enabled Its Dose Selection in the Phase 2b Study in Patients With Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine · 2026
7. D92-04 Exposure-response Relationships of Brensocatib in Adult and Adolescent Patients With Non-Cystic Fibrosis BronchiectasisAmerican Journal of Respiratory and Critical Care Medicine · 2026
8. Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint developmentAntimicrobial Agents and Chemotherapy · 2026
9. P-444. Population Pharmacokinetics (PPK) Analysis of Sulbactam-Durlobactam (SUD) to Support Dose Selection for Evaluation in a Clinical Trial in Pediatric Patients with Acinetobacter Baumannii-Calcoaceticus Complex (ABC) InfectionsOpen Forum Infectious Diseases · 2026
10. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Continuous Infusion Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)Open Forum Infectious Diseases · 2026
11. P-1229. Characterization of Ampicillin (AMP) and Vancomycin (VAN) Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Invasive Enterococcal Infection ModelOpen Forum Infectious Diseases · 2026
12. Identification of Ampicillin and Vancomycin In Vitro Susceptibility Test Interpretive Criteria for Enterococcus faecalis and Enterococcus faeciumOpen Forum Infectious Diseases · 2026
13. A Phase 1 Dose‐Escalation, Food Effect, and Drug–Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR‐1505, in Healthy VolunteersClinical Pharmacology in Drug Development · 2026
14. Optimizing Gentamicin Dosing in Pediatric Oncology PatientsThe Pediatric Infectious Disease Journal · 2025
15. Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinationsEBioMedicine · 2025
16. Engineered IL-18 variants with half-life extension and improved stability for cancer immunotherapyJournal for ImmunoTherapy of Cancer · 2025
17. Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trialNature Medicine · 2025
18. Population pharmacokinetic analyses for telavancin using data from healthy subjects and patients with infectionsAntimicrobial Agents and Chemotherapy · 2025
19. Chronic succinate exposure does not cause liver injuryAJP Endocrinology and Metabolism · 2025
20. P-1251. Pharmacometric Analyses to Support Dose Selection of Zoliflodacin, a First-in-Class Oral Antibiotic Being Developed for the Treatment of Uncomplicated GonorrheaOpen Forum Infectious Diseases · 2025